Anti-CDK19 monoclonal antibody

Pre-made anti-CDK19 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to CDK19/CDK19 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T98034-Ab-1/ GM-Tg-hg-T98034-Ab-2Anti-Human CDK19 monoclonal antibodyHuman
GM-Tg-rg-T98034-Ab-1/ GM-Tg-rg-T98034-Ab-2Anti-Rat CDK19 monoclonal antibodyRat
GM-Tg-mg-T98034-Ab-1/ GM-Tg-mg-T98034-Ab-2Anti-Mouse CDK19 monoclonal antibodyMouse
GM-Tg-cynog-T98034-Ab-1/ GM-Tg-cynog-T98034-Ab-2Anti-Cynomolgus/ Rhesus macaque CDK19 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T98034-Ab-1/ GM-Tg-felg-T98034-Ab-2Anti-Feline CDK19 monoclonal antibodyFeline
GM-Tg-cang-T98034-Ab-1/ GM-Tg-cang-T98034-Ab-2Anti-Canine CDK19 monoclonal antibodyCanine
GM-Tg-bovg-T98034-Ab-1/ GM-Tg-bovg-T98034-Ab-2Anti-Bovine CDK19 monoclonal antibodyBovine
GM-Tg-equg-T98034-Ab-1/ GM-Tg-equg-T98034-Ab-2Anti-Equine CDK19 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T98034-Ab-1/ GM-Tg-hg-T98034-Ab-2; GM-Tg-rg-T98034-Ab-1/ GM-Tg-rg-T98034-Ab-2;
GM-Tg-mg-T98034-Ab-1/ GM-Tg-mg-T98034-Ab-2; GM-Tg-cynog-T98034-Ab-1/ GM-Tg-cynog-T98034-Ab-2;
GM-Tg-felg-T98034-Ab-1/ GM-Tg-felg-T98034-Ab-2; GM-Tg-cang-T98034-Ab-1/ GM-Tg-cang-T98034-Ab-2;
GM-Tg-bovg-T98034-Ab-1/ GM-Tg-bovg-T98034-Ab-2; GM-Tg-equg-T98034-Ab-1/ GM-Tg-equg-T98034-Ab-2
Products NameAnti-CDK19 monoclonal antibody
Formatmab
Target NameCDK19
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-CDK19 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T98034-Ag-1Recombinant multi-species CDK19/ CDC2L6/ CDK11 protein


    Target information

    Target IDGM-T98034
    Target NameCDK19
    Gene ID23097,78334,309804,698292,612317,101083850,511802,100066791
    Gene Symbol and Synonyms2700084L06Rik,bA346C16.3,CDC2L6,CDK11,CDK19,DEE87,EIEE87,mKIAA1028
    Uniprot AccessionQ9BWU1
    Uniprot Entry NameCDK19_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000155111
    Target ClassificationKinase

    The target: CDK19, gene name: CDK19, also named as CDC2L6, CDK11, bA346C16.3. This gene encodes a protein that is one of the components of the Mediator co-activator complex. The Mediator complex is a multi-protein complex required for transcriptional activation by DNA binding transcription factors of genes transcribed by RNA polymerase II. The protein encoded by this gene is similar to cyclin-dependent kinase 8 which can also be a component of the Mediator complex. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.